UniPharma Co., Ltd. (TPEX:6621)
Taiwan
· Delayed Price · Currency is TWD 12.85
-0.20 (-1.53%)
Apr 29, 2026, 1:45 PM CST
UniPharma Revenue
In the year 2025, UniPharma had annual revenue of 88.44M TWD, down -5.36%. UniPharma had revenue of 44.13M in the half year ending December 31, 2025, a decrease of -16.06%.
Revenue
88.44M
Revenue Growth
-5.36%
P/S Ratio
5.26
Revenue / Employee
n/a
Employees
31
Market Cap
465.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.44M | -5.01M | -5.36% |
| Dec 31, 2024 | 93.46M | -9.77M | -9.46% |
| Dec 31, 2023 | 103.22M | -24.89M | -19.43% |
| Dec 31, 2022 | 128.11M | 22.72M | 21.56% |
| Dec 31, 2021 | 105.39M | -33.25M | -23.98% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Golden Biotechnology | 44.58M |
| Bioray Biotech | 230.06M |
| General Biologicals | 251.38M |
| Mediera | 229.85M |
| Original BioMedicals | 381.00K |
| Prince Pharmaceutical | 1.06B |
| Anxo Pharmaceutical | 883.22M |
| Excelsior Biopharma | 898.26M |